DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Bent Ejlertsen; Malgorzata K. Tuxen; Erik Hugger Jakobsen; Maj-Britt Jensen; Ann Knoop; Inger Højris; Marianne Ewertz; Eva Balslev; Peter Michael Vestlev; Julia Kenholm; Dorte L. Nielsen; Troels Bechmann; Michael Andersson; Søren Cold; Hanne M Nielsen; Else Maae; Dorte Carlsen; Henning T Mouridsen

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Bent Ejlertsen, Malgorzata K. Tuxen, Erik Hugger Jakobsen, Maj-Britt Jensen, Ann Knoop, Inger Højris, Marianne Ewertz, Eva Balslev, Peter Michael Vestlev, Julia Kenholm, Dorte L. Nielsen, Troels Bechmann, Michael Andersson, Søren Cold, Hanne M Nielsen, Else Maae, Dorte Carlsen, Henning T Mouridsen

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research › peer-review

Original language	English
Publication date	2016
Publication status	Published - 2016

Cite this

Ejlertsen, B., Tuxen, M. K., Hugger Jakobsen, E., Jensen, M-B., Knoop, A., Højris, I., Ewertz, M., Balslev, E., Vestlev, P. M., Kenholm, J., Nielsen, D. L., Bechmann, T., Andersson, M., Cold, S., Nielsen, H. M., Maae, E., Carlsen, D., & Mouridsen, H. T. (2016). DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer.

@conference{45b8b9a6001a48df9a954bad184e4594,

title = "DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer",

author = "Bent Ejlertsen and Tuxen, {Malgorzata K.} and {Hugger Jakobsen}, Erik and Maj-Britt Jensen and Ann Knoop and Inger H{\o}jris and Marianne Ewertz and Eva Balslev and Vestlev, {Peter Michael} and Julia Kenholm and Nielsen, {Dorte L.} and Troels Bechmann and Michael Andersson and S{\o}ren Cold and Nielsen, {Hanne M} and Else Maae and Dorte Carlsen and Mouridsen, {Henning T}",

year = "2016",

language = "English",

}

Ejlertsen, B, Tuxen, MK, Hugger Jakobsen, E, Jensen, M-B, Knoop, A, Højris, I, Ewertz, M, Balslev, E, Vestlev, PM, Kenholm, J, Nielsen, DL, Bechmann, T, Andersson, M, Cold, S, Nielsen, HM, Maae, E, Carlsen, D & Mouridsen, HT 2016, 'DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer'.

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer. / Ejlertsen, Bent; Tuxen, Malgorzata K.; Hugger Jakobsen, Erik et al.

2016.

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research › peer-review

TY - ABST

T1 - DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

AU - Ejlertsen, Bent

AU - Tuxen, Malgorzata K.

AU - Hugger Jakobsen, Erik

AU - Jensen, Maj-Britt

AU - Knoop, Ann

AU - Højris, Inger

AU - Ewertz, Marianne

AU - Balslev, Eva

AU - Vestlev, Peter Michael

AU - Kenholm, Julia

AU - Nielsen, Dorte L.

AU - Bechmann, Troels

AU - Andersson, Michael

AU - Cold, Søren

AU - Nielsen, Hanne M

AU - Maae, Else

AU - Carlsen, Dorte

AU - Mouridsen, Henning T

PY - 2016

Y1 - 2016

M3 - Conference abstract for conference

ER -